Postural orthostatic tachycardia syndrome-like symptoms following COVID-19 vaccination: An overview of clinical literature
Abstract
BACKGROUND:
Postural Orthostatic Tachycardia Syndrome (POTS) is a common condition affecting more than 170 people per 100,000 population. However, POTS following COVID-19 vaccination remains a rare reporting in the medical literature.
OBJECTIVE:
We, herein, summarize and highlight the evidence that has been reported regarding POTS-like symptoms following COVID-19 vaccination.
METHODS:
We conducted a literature search and summarized the findings in the form of a narrative commentary. All types of publications (case reports/series, original articles, letters to editors, brief communications etc.) in English language were included.
RESULTS:
Whilst the exact pathogenetic mechanism behind POTS is yet to elucidated, there has been increasing evidence pointing towards an autoimmune dysfunction. Females were found to be predominantly affected (72%) with age range from 17 years to 52 years. Additionally, it seems that POTS-like symptoms could be triggered after immunization with Pfizer- BioNTech, Moderna, and Oxford-AstraZeneca COVID-19 vaccines. The symptoms typically appear within the first week, depending upon previous exposure to the virus and presence of other systemic conditions. In some patients, the condition is self-resolving. However, in others, non-pharmacological interventions coupled with negative ionotropic medications can be used for symptomatic management of the patients.
CONCLUSIONS:
Timely diagnosis and proper treatment are quintessential for ensuring early alleviation (and in some cases complete resolution) of symptoms. Furthermore, there may be episodes of relapse. Overall prognosis of the new-onset POTS-like symptoms is difficult to predict based on current literature.
1.Introduction
Postural Orthostatic Tachycardia Syndrome (POTS) is defined as the presence of chronic symptoms of orthostatic intolerance for six months or longer, associated with an increased heart rate
POTS following COVID-19 vaccination is considered as an extremely rare event. However, a recent increase in reports of its incidence in the medical literature has attracted the attention of the medical community [4, 5, 6, 7, 8, 9, 10, 11]. Although the association and pathophysiological relationship between these two events remain to be fully elucidated, a variety of mechanisms have been proposed including neuroendocrine dysfunction, neuropathy, and autoimmunity [12]. Therefore, in the present paper, we summarize and highlight the relevant evidence that has been reported in the literature to assist and enlighten physicians, nurses, and healthcare providers in the diagnosis and management of such patients.
2.Pathophysiology of POTS
Standing in an upright position results in a gravitational shift of blood (approximately 500–800 mL) from the upper body to the abdomen and legs. This causes a drop in the systemic blood pressure [13]. In healthy individuals, there are regulatory feedback pathways between the musculoskeletal, nervous, and cardiovascular systems that compensate for this shifting of vascular volume. When a lower blood pressure is sensed by the baroreceptors in the aortic arch and atrial wall, sympathetic outflow increases (with concomitant depression of parasympathetic signals), leading to increased heart rate and peripheral vasoconstriction. This increases both the cardiac output and systemic vascular resistance, thereby preventing a fall in the blood pressure. In addition, muscular contraction (mainly of the calf muscles) pushes the blood upwards into the inferior vena cava, providing an upstream flow of blood to the heart [13].
In patients with POTS however, there are disruptions in these feedback pathways. Excessive sympathetic outflow (causing orthostatic hypertension), down-regulated venous receptors (causing decreased venous return), decreased plasma aldosterone-to-renin ratio (causing reduced sodium retention and plasma volume expansion), and elevated angiotensin II without concomitant hypertension (decreased sensitivity to vasoconstrictive effects) are some of the mechanisms that have been identified in the pathophysiology of POTS [13]. Other factors that have been identified as precipitating POTS include hypovolemia, deconditioning, neuroendocrine dysfunction (central hyperadrenergic state), neuropathy, infection, medications (antihypertensives, antipsychotics), surgery, pregnancy, concussion, and autoimmunity [14].
3.Autoimmunity and POTS
Despite the apparent lack of detectable antibodies in POTS patients, there are several features that POTS patients showcase which are indicative of an underlying autoimmune pathophysiology. Like other autoimmune conditions (lupus, rheumatoid arthritis), POTS predominantly affects women, has post-viral onset, and showcases elevated autoimmune markers [15, 16]. Additionally, some reports have suggested that symptoms and biomarkers tend to respond well to a high-dose corticosteroid treatment [17]. It is also interesting that POTS is reported as a common complaint in patients suffering from other autoimmune conditions [1].
It is thought that given the role of autoimmune system in POTS, it could also be classified as an inflammatory disorder [18]. Indeed, studies have shown an increased levels of pro-inflammatory cytokines including IL-1
However, it should be noted that concerns have been raised about the ability of these autoantibody assays (ELISA-based; enzyme-linked immunosorbent assay) to discriminate between healthy controls and individuals with POTS [22]. Differences in assay sensitivity and method of quantification of autoantibodies limit their utility. In addition, the detection of these autoantibodies in healthy controls complicates the interpretation of these assays [22].
Table 1
Characteristics of patients reported to have developed POTS-like symptoms following COVID-19 Vaccination
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | |
|---|---|---|---|---|---|---|
| Age | 40 years | 42 years | 46 years | 37 years | 21 years | 46 years |
| Gender | Male | Male | Female | Female | Female | Female |
| Country | South Korea | USA | USA | USA | USA | USA |
| First dose | Moderna | Pfizer-BioNTech | Pfizer-BioNTech | Moderna | Pfizer-BioNTech | Pfizer-BioNTech |
| Second dose | – | – | – | – | – | – |
| Third dose | – | – | – | – | – | – |
| POTS Symptom onset | 7-days post first dose | 24 hours post first dose | 1.5 hours post first dose | 1 week post first dose | 12 days post first dose | 2 weeks post first dose |
| Symptoms | Intermittent headache, palpitation, fatigue, and dyspnoea | Generalized fatigue, headache, and myalgia. On day 7 also developed sinus tachycardia and presyncope episodes | Erythema, urticaria, paraesthesia, light-headedness, tremors, rapid heart rate, Raynaud’s Phenomenon, and marked fatigue | Light-headedness, racing heart, weakness, tiredness, difficulty concentrating, blurry vision, shakiness, vertigo, and clamminess | Light headache, palpitation, weakness, and difficulty thinking | Lightheadedness, nausea, fatigue, poor concentration, palpitations, and brain fog |
| Other medical conditions | None | Hypothyroidism and B12 vitamin deficiency (both are controlled using medications) | None | Seasonal allergy and depression. Patient takes vortioxetine (serotonin reuptake inhibitor) | None | None |
| Past medical history | Not significant | Left-sided orchiectomy for cryptorchidism | Allergic rhinitis, COVID-19 infection (9 months before vaccination) | Not significant | Not significant | Not significant |
| Previously known reactions to other vaccines | None | None | – | – | – | – |
| Medical Interventions | Propranolol for 2 months | Lifestyle modification (compression stocking, increased sodium intake) | Lifestyle modification and Ivabradine | Ivabradine | Metoprolol and Fludrocortisone | Fludrocortisone and Propranolol |
| Resolution | Five months from symptom onset | Patient suffers from symptoms at time of publication | Patient suffers from mild symptoms still 8 months post treatment start | Patient reported improvement in symptoms | Patient reported improvement in symptoms | Patient reported improvement in symptoms |
| Reference | Park et al., [4] | Reddy et al., [5] | Hermel et al., [6] | Eldokla and Numan [7] | Eldokla and Numan [7] | Eldokla and Numan |
|
Table 1, continued | ||||||
|---|---|---|---|---|---|---|
| Patient 7 | Patient 8 | Patient 9 | Patient 10 | Patient 11 | Patient 12 | |
| Age | 19 years | 17 years | 29 years | 43 years | 30 years | 52 years |
| Gender | Female | Female | Male | Male | Female | Male |
| Country | USA | USA | Australia | UK | UK | USA |
| First dose | Pfizer-BioNTech | Pfizer-BioNTech | Oxford-AstraZeneca | Pfizer-BioNTech | Oxford-AstraZeneca | Pfizer-BioNTech |
| Second dose | Pfizer-BioNTech | Pfizer-BioNTech | – | Pfizer-BioNTech | – | Pfizer-BioNTech |
| Third dose | – | – | – | Pfizer-BioNTech | – | – |
| POTS Symptom onset | 18 days post second dose | 3 weeks post second dose | 4 days post first dose | 1 to 2 weeks post second dose; 2–3 days post third dose | 6 hours post first dose | After second dose |
| Symptoms | Dizziness, headache, nausea, bloating, excessive sweating, and fatigue | Syncope, fatigue, chest tightness, nausea, and heat intolerance | Intermittent paraesthesia, palpitations, racing hearbeat, dizziness, and worsening of paraesthesia and skin colour | Dizziness, leg weakness, light-headedness, brain fog, word-finding difficulties | Dizziness, nausea, weakness, bradykinesia, brain fog, early waking, fatigue, “jelly-legs”, changes to walking gait, | Burning and stabbing feeling, orthostatic intolerance, syncope, supraventricular tachycardia, tinnitus |
| Other medical conditions | None | None | None | None | Patient uses Naproxen, Lansoprazole, Dihydrocodeine, Melatonin | – |
| Past medical history | Not significant | Not significant | Not significant | Suspected COVID-19 infection (8 months before vaccination) | Fatigue and sleep disturbances | – |
| Previously known reactions to other vaccines | – | – | – | – | – | – |
| Medical Interventions | Salt tablets and Propranolol | Scopolamine patches, Salt tablets and Propranolol | 5-week course of steroid (no effect); lifestyle modifications | Intramusular hydroxocobalamin followed by oral cyanocobalamin | Intramusular hydroxocobalamin therapy | Nadolol, Gabapentin, Amitriptyline, and trazodone (no effect); Five plasma exchange sessions |
| Resolution | Patient reported improvement in symptoms | Patient reported improvement in symptoms | Patient has some improvement still 6 months post treatment start | Eight weeks from treatment | Patient reported improvement in symptoms | Patient reported improvement in symptoms |
| Reference | Eldokla and Numan [7] | Eldokla and Numan [7] | Karimi [8] | Carroll et al., [9] | Carroll et al., [9] | Schelke et al., |
|
Table 1, continued | ||||||
|---|---|---|---|---|---|---|
| Patient 13 | Patient 14 | Patient 15 | Patient 16 | Patient 17 | Patient 18 | |
| Age | 31 to 40 years | 31 to 40 years | 31 to 40 years | 41 to 50 years | 31 to 40 years | 31 to 40 years |
| Gender | Female | Female | Female | Female | Female | Female |
| Country | USA | USA | USA | USA | USA | USA |
| First dose | Oxford-AstraZeneca | Moderna | Pfizer-BioNTech | Moderna | Moderna | Moderna |
| Second dose | – | Moderna | Pfizer-BioNTech | – | – | Moderna |
| Third dose | – | – | – | – | – | – |
| POTS Symptom onset | 2 hour post first dose | 2 days post second dose | 10 days post second dose | 2 days post first dose | 6 days post first dose | 5 days post second dose |
| Symptoms | Severe paresthesia in limbs, tachycardia, blood pressure fluctuation, intermittent internal tremor, cognitive complaints | Orthostasis, fluctuation in heart rate and blood pressure, nausea, diarrhea, Paresthesia in face, upper and lower limbs; internal tremor | Severe orthostatic tachycardia, paler, diarrhea, fluctuation in blood pressure | Intermittent paresthesia, burning and numbness in face, hands and feet. Mild right-hand weakness and episodic positional palpitation | Exercise intolerance; fasciculations in all limbs; internal tremor, facial paresthesia; band like tightness in chest; cognitive changes; episodic positional palpitations | Paresthesia and burning sensation in V1 distribution of trigeminal nerves; positional palpitation and dizziness with activity |
| Other medical conditions | – | – | – | – | – | – |
| Past medical history | Probable history of COVID-19 and family history of Sjrogen’s disease | Family history of psoriasis | Family history of rheumatoid arthritis | Not significant | Not significant | Not significant |
| Previously known reactions to other vaccines | – | – | – | – | – | – |
| Medical Interventions | – | – | – | – | – | – |
| Resolution | – | – | – | – | – | – |
| Reference | Sayafi et al., [11] | Sayafi et al., [11] | Sayafi et al., [11] | Sayafi et al., [11] | Sayafi et al., [11] | Sayafi et al., |
4.POTS-like symptoms following COVID-19 vaccination
We identified 18 cases of reported POTS following COVID-19 vaccination from the available literature (Table 1). Females were found to be predominantly affected (72%) with an age range of 17 to 52 years. Most cases were reported from the United States (US) followed by the United Kingdom (UK), Australia, and South Korea. 11 cases (61%) were found to develop POTS-like symptoms after the first dose of COVID-19 vaccine, while seven cases developed symptoms after the second dose of the COVID-19 vaccine. A single case was reported to develop the symptoms twice – after the second and the third vaccine doses (Patient 10; Table 1). We further found that most of the cases (83%) were associated with mRNA vaccines – six cases post-vaccination with Moderna, and nine cases post-vaccination with Pfizer-BioNTech. The remaining three cases were reported post-vaccination with Oxford-AstraZeneca.
The onset of POTS-like symptoms varied from a few hours to three weeks after vaccination. In most cases, patients complained of dizziness, tachycardia, brain fog, headache, nausea, weakness, paraesthesia, and episodes of syncope while standing. Improvement in symptoms has been reported with recumbency or sitting. In addition, it appears that many patients who developed these symptoms post-vaccination, also developed vitamin B12 (cobalamin) deficiency. Correcting this deficiency seemed to improve patient’s symptoms. Hypovitaminosis, including vitamin D, B1, B12, and iron deficiency, has been previously reported in a subset of POTS patients [23, 24, 25]. However, the exact relationship between hypovitaminosis and POTS is still not clear. Moreover, included studies didn’t report baseline vitamin B12 levels and dietary intake. Pregnant patients, vegetarians, the older individuals, and those living in developing countries have been shown to have higher risk of vitamin B12 deficiency [26, 27].
Nevertheless, the role of vitamin B12 in neurologic dysfunction is well documented [26]. A deficiency of cobalamin may result in a peripheral neuropathy that produces autonomic manifestations that would tend to be like orthostatic hypotension. This may partially explain the relief of symptoms reported by patients upon correction of cobalamin deficiency. The treatment approach generally, varied between studies (mostly due to differences in symptoms, medical history, and national guidelines). Most patients reported improvement in symptoms with the therapy they received.
5.COVID-19 vaccination induced autoimmunity
Autoimmunity may be the key pathogenetic pathway of post-vaccination POTS-like symptoms, particularly with adjuvanted mRNA vaccines. However, given the small number of reports published in the literature describing POTS-like symptoms after vaccination, concerns have been raised that patients are either being undiagnosed or misdiagnosed, leading to underreporting and underappreciation of its true incidence [1]. Consider the difficulty faced by clinicians in distinguishing POTS from postural vasovagal syncope, a transient loss of consciousness caused by reduced cerebral blood flow. This leads to difficulties in determining the exact pathogenetic mechanism responsible for the phenomenon.
It has been postulated that autonomic dysfunction following COVID-19 infection could be modulated by cross-reaction of anti-SARS-COV-2 antibodies with components of autonomic nervous system, including ganglia, nerve fibres, and receptors [12]. A similar argument could also be advanced in the context of the antibodies generated in response to COVID-19 vaccination [11]. Furthermore, it is possible that these autoantibodies remain undetected in patients who developed autonomic neuropathies post-vaccination [11].
In the case of mRNA-based immunizers, the vaccine triggers host cells to translate the genetic code of the virus and produce the viral spike protein target, which acts as an intracellular antigen. The immune system then mounts its adaptive response, producing and releasing neutralizing antibodies that block viral entry [28]. Given the possibility of autonomic cross-reactivity of vaccine-generated antibodies, several pathways have been proposed. Reactivity with
A recently posted preprint showed that following COVID-19 vaccination, a third of the patients who underwent skin biopsy had subthreshold nerve fibre density, thereby fulfilling the pathological criteria for new onset small fibre neuropathy [11]. Other study patients had demonstrated either borderline low density or axonal swelling with reduced conduction velocities in distal leg [11]. The authors also reported increased C4d deposition on endothelial cells in skin biopsy samples and the presence of oligoclonal bands in cerebrospinal fluid (CSF). Interestingly, most of the study participants were females and responded to immunotherapy, potentially pointing towards the role of the autoimmune system [11].
Since the reports indicated that patients received different vaccines (Pfizer-BioNTech, Moderna, and Oxford-AstraZeneca), we could potentially rule out the differences in vaccine platforms as a potential cause of POTS following vaccination. This is also evident from the fact that POTS has also been widely reported following Human Papillomavirus (HPV) and Influenza (H1N1) vaccinations [1, 31, 32].
6.POTS-like symptoms or usual side-effects of vaccination
Diagnosis for POTS in a suspected patient requires fulfilment of clinical criteria, identification of comorbid conditions, medication use, and exclusion (along with severity assessment) of conditions that could cause or mimic the autonomic syndrome. A thorough physical, cardiologic, and neurologic examination is needed to differentiate between exaggerated orthostatic tachycardia in the absence of orthostatic hypotension and to rule out any gross structural pathology. A basic workup should include a complete blood count, serum electrolytes, thyroid and cardiac function tests, and electrocardiogram (ECG). For a more accurate diagnosis, it is essential to perform clinical examinations before vaccination and several weeks after vaccination [33].
A recent large study cohort showed that the odds of developing POTS and POTS-associated diagnoses (dysautonomia, mast cell disorder, fatigue, and Ehlers–Danlos syndrome) were higher three months after COVID-19 vaccination than three months preceding vaccination [34]. In addition, POTS and POTS-associated diagnoses were among the top five disease diagnoses and were generally similar across age groups, sex, ethnicities, types of vaccine, and the dose number received. Since the diagnosis of POTS requires 3–6 months of symptoms, it is not possible to classify the symptoms noted immediately after vaccination as POTS. Rather it may be appropriate to describe them as “POTS-like”.
It appears that the symptoms of POTS-like syndrome post-vaccination are usually recorded as late reactions, usually within the first seven days after vaccination. This temporal association maybe noteworthy in distinguishing between common vaccine side effects and vaccine-induced POTS-like syndrome. Although the most common side effects of the COVID-19 vaccines are fatigue and headache, the duration of symptoms is usually one to three days and patients don’t experience episodes of presyncope or syncope and sinus tachycardia [35, 36]. Thus, the onset of symptoms and duration of approximately one week after vaccination with the mRNA vaccine may prove to be indicative for the diagnosis of POTS-like symptoms, especially in patients with no prior noticeable medical history. Nonetheless, a few cases have been described in which the patients developed POTS-like symptoms within hours to two days after COVID-19 vaccination. What distinguishes these cases are the prior history of COVID-19 infection and/or other chronic conditions, which could potentially explain the accelerated immune response in these cases (Table 1).
7.Patient management
Treatment for these patients is aimed at alleviating symptoms, improving blood volume, and lifestyle changes. Symptoms could be eased by wearing compression stockings to improve venous return in the lower extremities and increasing sodium intake [37]. Given the multifactorial pathogenesis of POTS itself, several studies have compared and evaluated the efficacy of various treatment approaches, including intravascular volume expansion, vasopressor therapy, heart rate reduction, and miscellaneous therapies [38]. Based on current evidence, the Canadian Cardiovascular Society recommends non-pharmacological therapy as the first line management approach – withdrawal of exacerbating medications, increasing blood volume with dietary interventions, use of compression stockings, adoption of head-up tilt sleeping position, and semi-recumbent exercises [39]. For pharmacological therapy, the society recommends midodrine (
8.Prognosis
An evaluation of the risk-benefit ratio shows that there is currently no evidence to support the propaganda against vaccination because of its adverse effects, with its benefits far outweighing its drawbacks. POTS-like symptoms after COVID-19 vaccination could be controlled by a combination of lifestyle changes and medications (if necessary). The prognosis of patients is difficult to predict based on the available literature. According to a Mayo Clinic study of adolescents with POTS symptoms (possibly different mechanism than vaccine induced symptoms), 37% of patients no longer met the tilt criteria for POTS after one year [40]. However, to formulate risk factors and accurate prognosis for POTS-like symptoms after vaccination, longer follow-up studies are needed.
9.Conclusions
POTS-like symptoms following COVID-19 vaccination is a heterogeneous condition characterized by prolonged episodes of tachycardia, syncope, or presyncope. The onset of symptoms appears to be independent of the type of vaccine administered, although the onset may vary depending on previous history of COVID-19 infection or systemic diseases. These symptoms usually appear on the first day of injecting the vaccine and worsen within seven days. The pathophysiology of the symptoms could possibly relate to many mechanisms, with the predominant role potentially being hypothesized as autoimmune. Although orthostatic intolerance is very uncomfortable for patients, it does not significantly increase the risk of mortality. If patients seek timely diagnosis and appropriate treatment, their symptoms may relieve over time.
Ethical approval
Not applicable.
Funding
The present paper didn’t receive any external funding and was self-supported by the authors.
Author contributions
PTV, NJ, TTT, THT, and NTHH conceptualized the present perspective paper whilst all authors were involved in data collection and preparation of the initial draft of the manuscript. PTV and NJ were responsible for revising the manuscript. Supervision was done by AR. All authors have read and agreed to the final version of the paper for publication.
Acknowledgments
None.
Conflict of interest
The authors declare no conflicts of interest.
References
[1] | S. Dahan, L. Tomljenovic and Y. Shoenfeld, Postural Orthostatic Tachycardia Syndrome (POTS)–A novel member of the autoimmune family, Lupus 25: ((2016) ), 339–342. |
[2] | S.R. Raj and B.D. Levine, Postural Tachycardia Syndrome (POTS) Diagnosis and Treatment: Basics and New Developments, Expert Analysis, American College of Cardiology, ((2013) ). |
[3] | H.M. Cline and A. Einhardt, Postural orthostatic tachycardia syndrome: A conundrum for patients and healthcare providers, The Nurse Practitioner 47: ((2022) ), 12–19. |
[4] | J. Park, S. Kim, J. Lee and J.Y. An, A case of transient POTS following COVID-19 vaccine, Acta Neurologica Belgica 122: ((2022) ), 1081–1083. |
[5] | S. Reddy, S. Reddy and M. Arora, A case of postural orthostatic tachycardia syndrome secondary to the messenger RNA COVID-19 vaccine, Cureus 13: ((2021) ), e14837. |
[6] | M. Hermel, M. Sweeney, E. Abud, K. Luskin, J.P. Criado, R. Bonakdar, et al., COVID-19 vaccination might induce postural orthostatic tachycardia syndrome: A case report, Vaccines (Basel) 10: ((2022) ), 991. |
[7] | A.M. Eldokla and M.T. Numan, Postural orthostatic tachycardia syndrome after mRNA COVID-19 vaccine, Clinical Autonomic Research 32: ((2022) ), 307–311. |
[8] | K. Karimi Galougahi, Autonomic dysfunction post-inoculation with ChAdOx1 nCoV-19 vaccine, European Heart Journal Case Reports 5: ((2021) ), ytab472. |
[9] | H.A. Carroll, E. Millar and K.A. Deans, Vitamin B12 and D deficiency as cofactors of COVID-19 vaccine-induced chronic neurological adverse reactions: Two cases and a hypothesis, Preprint, Research Square ((2022) ), 1–33. |
[10] | M.W. Schelke, S. Barcavage, E. Lampshire and T.H. Brannagan 3rd, Post-COVID-19 vaccine small-fiber neuropathy and tinnitus treated with plasma exchange, Muscle Nerve 66: ((2022) ), E21–E23. |
[11] | F. Safavi, L. Gustafson, B. Walitt, T. Lehky, S. Dehbashi, A. Wiebold, et al., Neuropathic symptoms with SARS-CoV-2 vaccination, Preprint, medRxiv, 2022. |
[12] | S. Blitshteyn and S. Whitelaw, Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: A case series of 20 patients, Immunologic Research 69: ((2021) ), 205–211. |
[13] | H. Kesserwani, Postural orthostatic tachycardia syndrome misdiagnosed as anxiety: A case report with a review of therapy and pathophysiology, Cureus 12: ((2020) ), e10881. |
[14] | A. Fedorowski, Postural orthostatic tachycardia syndrome: Clinical presentation, aetiology and management, Journal of Internal Medicine 285: ((2019) ), 352–366. |
[15] | S. Zhao and V.H. Tran, Postural orthostatic tachycardia syndrome, in: StatPearls [Internet]. Treasure Island: StatPearls Publishing, Florida, United States, ((2022) ). |
[16] | M. Bryarly, L.T. Phillips, Q. Fu, S. Vernino and B.D. Levine, Postural orthostatic tachycardia syndrome: JACC focus seminar, Journal of the American College of Cardiology 73: ((2019) ), 1207–1228. |
[17] | S. Vernino, Autoimmune autonomic disorders, Continuum: Lifelong Learning in Neurology (Minneap Minn) 26: ((2020) ), 44–57. |
[18] | W.T. Gunning 3rd, S.M. Stepkowski, P.M. Kramer, B.L. Karabin and B.P. Grubb, Inflammatory biomarkers in postural orthostatic tachycardia syndrome with elevated g-protein-coupled receptor autoantibodies, Journal of Clinical Medicine 10: ((2021) ), 623. |
[19] | L.E. Okamoto, S.R. Raj, A. Gamboa, C.A. Shibao, A.C. Arnold, E.M. Garland, et al., Sympathetic activation is associated with increased IL-6, but not CRP in the absence of obesity: Lessons from postural tachycardia syndrome and obesity, American Journal of Physiology Heart and Circulatory Physiology 309: ((2015) ), H2098–2107. |
[20] | M.J. Thieben, P. Sandroni, D.M. Sletten, L.M. Benrud-Larson, R.D. Fealey, S. Vernino, et al., Postural orthostatic tachycardia syndrome: The Mayo clinic experience, Mayo Clinic Proceedings 82: ((2007) ), 308–313. |
[21] | W.T. Gunning 3rd, B.L. Karabin, T.M. Blomquist and B.P. Grubb, Postural orthostatic tachycardia syndrome is associated with platelet storage pool deficiency, Medicine (Baltimore) 95: ((2016) ), e4849. |
[22] | J. Hall, K.M. Bourne, S. Vernino, V. Hamrefors, I. Kharraziha, J. Nilsson, et al., Detection of G protein-coupled receptor autoantibodies in postural orthostatic tachycardia syndrome using standard methodology, Circulation 146: ((2022) ), 613–622. |
[23] | S. Blitshteyn, Vitamin B1 deficiency in patients with postural tachycardia syndrome (POTS), Neurological Research 39: ((2017) ), 685–688. |
[24] | T. Öner, B. Guven, V. Tavli, T. Mese, M.M. Yilmazer and S. Demirpence, Postural orthostatic tachycardia syndrome (POTS) and vitamin B12 deficiency in adolescents, Pediatrics 133: ((2014) ), e138–142. |
[25] | I.T. Jarjour and L.K. Jarjour, Low iron storage and mild anemia in postural tachycardia syndrome in adolescents, Clinical Autonomic Research 23: ((2013) ), 175–179. |
[26] | E. Azzini, A. Raguzzini and A. Polito, A brief review on vitamin B12 deficiency looking at some case study reports in adults, International Journal of Molecular Sciences 22: ((2021) ), 9694. |
[27] | R. Pawlak, S.E. Lester and T. Babatunde, The prevalence of cobalamin deficiency among vegetarians assessed by serum vitamin B12: A review of literature, European Journal of Clinical Nutrition 68: ((2014) ), 541–548. |
[28] | F.P. Polack, S.J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, et al., Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine, New England Journal of Medicine 383: ((2020) ), 2603–2615. |
[29] | H.I. Mustafa, E.M. Garland, I. Biaggioni, B.K. Black, W.D. Dupont, D. Robertson, et al., Abnormalities of angiotensin regulation in postural tachycardia syndrome, Heart Rhythm 8: ((2011) ), 422–428. |
[30] | T. Umapathi, M.Q.W. Poh, B.E. Fan, K.F.C. Li, J. George and J.Y.L. Tan, Acute hyperhidrosis and postural tachycardia in a COVID-19 patient, Clinical Autonomic Research 30: ((2020) ), 571–573. |
[31] | C-K. Tsai, H. Chu and C.-A. Cheng, Novel H1N1 influenza vaccine the cause of postural orthostatic tachycardia syndrome followed by cerebral hypoperfusion, Journal of Medical Sciences 31: ((2011) ), 91–93. |
[32] | S. Blitshteyn and J. Brook, Postural tachycardia syndrome (POTS) with anti-NMDA receptor antibodies after human papillomavirus vaccination, Immunologic Research 65: ((2017) ), 282–284. |
[33] | R. Rubin, Large cohort study finds possible association between postural orthostatic tachycardia syndrome and COVID-19 vaccination but far stronger link with SARS-CoV-2 infection, Journal of the American Medical Association (JAMA) 329: ((2023) ), 454–456. |
[34] | A.C. Kwan, J.E. Ebinger and J. Wei, C.N. Le, J.R. Oft, R. Zabner, et al., Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination and SARS-Cov-2 Infection, Nature Cardiovascular Research 1: ((2022) ), 1187–1194. |
[35] | J.H. Im, E. Kim, E. Lee, Y. Seo, Y. Lee, Y. Jang, et al., Adverse events with the Pfizer-BioNTech COVID-19 vaccine among korean healthcare workers, Yonsei Medical Journal 62: ((2021) ), 1162–1168. |
[36] | I.M. Dighriri, K.M. Alhusayni, A.Y. Mobarki, I.S. Aljerary, K.A. Alqurashi, F.A. Aljuaid, et al., Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) side effects: A systematic review, Cureus 14: ((2022) ), e23526. |
[37] | M. Hermel, M. Sweeney, Y.M. Ni, R. Bonakdar, D. Triffon, C. Suhar, et al., Natural supplements for COVID19-background, rationale, and clinical trials, Jorunal of Evidence-Based Integrative Medicine 26: ((2021) ), 2515690X211036875. |
[38] | R. Wells, A.D. Elliott, R. Mahajan, A. Page, V. Iodice, P. Sanders, et al., Efficacy of therapies for postural tachycardia syndrome: A systematic review and meta-analysis, Mayo Clinic Proceedings 93: ((2018) ), 1043–1053. |
[39] | S.R. Raj, J.C. Guzman, P. Harvey, L. Richer, R. Schondorf, C. Seifer, et al., Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and related disorders of chronic orthostatic intolerance, The Canadian Journal of Cardiology 36: ((2020) ), 357–372. |
[40] | K. Kimpinski, J.J. Figueroa, W. Singer, D.M. Sletten, V. Iodice, P. Sandroni, et al., A prospective, 1-year follow-up study of postural tachycardia syndrome, Mayo Clinic Proceedings 87: ((2012) ), 746–752. |
